Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin. - Wikidata - wikimedia - TriplyDB

Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin.

Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin.

http://www.wikidata.org/entity/Q33387696

about

Critical appraisal of trastuzumab in treatment of advanced stomach cancer Evaluation and treatment of malignant ascites secondary to gastric cancer Chemotherapy beyond second-line in advanced gastric cancer Irinotecan plus mitomycin C as second-line chemotherapy for advanced gastric cancer resistant to fluoropyrimidine and Cisplatin: a retrospective study.Third-line docetaxel chemotherapy for recurrent and metastatic gastric cancer.Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy.Cost-effectiveness and safety of ramucirumab plus paclitaxel chemotherapy in the treatment of advanced and recurrent gastric cancer.Safety and continuity of second- and third-line therapy with paclitaxel or irinotecan for advanced and recurrent gastric cancer.Efficacy and safety of irinotecan monotherapy as third-line treatment for advanced gastric cancer.Availability of irinotecan in a second-line setting confers survival benefit to patients with advanced gastric cancer refractory to fluoropyrimidine-based regimens Metastatic gastric cancer treatment: Second line and beyond.Pharmaceutical care for patients undergoing s-1 plus Cisplatin therapy for unresectable recurrent gastric cancer.Efficacy of weekly paclitaxel in patients with advanced gastric cancer refractory to docetaxel-based chemotherapy.Efficacy and safety of taxane monotherapy in advanced gastric cancer refractory to triplet chemotherapy with docetaxel, cisplatin, and S-1: a multicenter retrospective study.5 fluorouracil, leucovorin, and irinotecan (FOLFIRI) as a third-line chemotherapy treatment in metastatic gastric cancer, after failure of fluoropyrimidine, platinum, anthracycline, and taxane.Dairy milk fat augments paclitaxel therapy to suppress tumour metastasis in mice, and protects against the side-effects of chemotherapy.Prognostic factor analysis of third-line chemotherapy in patients with advanced gastric cancer.Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes.Second-line treatments: moving towards an opportunity to improve survival in advanced gastric cancer?Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: A population-based outcomes study.

P2860

Q24604411-5DB70F0E-B56C-4BCB-938A-94EA1BD3CF3D Q26780301-1EDB9AF3-9535-4F5C-9CDC-B8248228003F Q26798288-5E13B240-A95E-4495-8B10-01CB628B3EEF Q33400558-A01D8B10-E96B-491B-9989-B8768FF71A01 Q33407797-ECC30022-6FE7-401E-A5D2-46F6BD93635B Q38599120-A041B6F2-B0C3-45C7-AF65-75196B2BF230 Q38823650-04B32DDB-B1DA-423C-9CF9-7328459A87CD Q38956887-359C03A3-DCAD-4548-BDA9-84FEC85AE7F6 Q39448583-5B0C60E3-2748-456C-8976-A32BA9858598 Q41823021-7D188F3F-5C37-4550-85BD-EA040F1CD114 Q42957434-D96DBA0F-7D5B-4FF4-9000-AC8B76C14C8B Q43556517-791AC7FD-F69A-4161-92F6-CC8F9BDB66A6 Q43968364-9ABDA4B7-9E29-49A8-A49E-FA4368F0F174 Q48090713-CEE971D2-01E3-42EC-9D7E-FBBABF9E9D7D Q49895422-0B6E295C-AB2D-48B6-A8AA-DA84A6CE1988 Q50529905-B25495F5-C5DF-4AD5-86D3-A4FE899ED81B Q51046395-BB675DAE-152C-40EE-B995-9CA2FF8F00C5 Q53676322-7E9E1B16-63D4-4589-A7EA-5193A23FEC34 Q54970742-DA650F5C-D15A-4B35-AB24-2442BBEE128B Q55379237-474723B7-4EDF-4EA3-812D-BA530F9E654B

P2860

Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin.

http://www.wikidata.org/entity/Q33387696

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Weekly paclitaxel for heavily ...... il, irinotecan, and cisplatin.

@ast

Weekly paclitaxel for heavily ...... il, irinotecan, and cisplatin.

@en

type

label

Weekly paclitaxel for heavily ...... il, irinotecan, and cisplatin.

@ast

Weekly paclitaxel for heavily ...... il, irinotecan, and cisplatin.

@en

prefLabel

Weekly paclitaxel for heavily ...... il, irinotecan, and cisplatin.

@ast

Weekly paclitaxel for heavily ...... il, irinotecan, and cisplatin.

@en

P1433

Q33387696-B9007448-9EAF-414B-8EBD-E1F7992D7DE2

P1476

Q33387696-494401E9-0E06-4C61-8C5B-FD24A5553E10

P2093

Q33387696-0D69B556-B57A-4411-83C7-BE91460FBB3F

Q33387696-0F772005-591F-4E23-B1A6-4C34BA525A7A

Q33387696-12A39E57-9F58-4B1B-B31C-4C87441F90CB

Q33387696-1F87EB23-59D9-4D8F-8AA8-DE9A786CAC79

Q33387696-295C9215-2DEA-4F9A-8256-BE52E8845C18

Q33387696-31B40AEA-539C-4B43-B32C-A4B101CDF086

Q33387696-38A1B785-BD19-4C78-86B9-73BE7391171C

Q33387696-4FB92E42-F933-4CA7-A924-D372C9263162

Q33387696-51D94C33-F21D-4E74-8F62-871591130F15

Q33387696-8352CEFD-E519-447C-9A64-C21590965063

P2860

Q33387696-240D948C-1CEB-4992-A480-3FCBB3D14363

Q33387696-9454A49A-84FE-4B30-A388-5D6F1384DE88

P2888

Q33387696-F60FDF91-0BA6-4958-9643-5EB675AAF984

P304

Q33387696-E9B8BE48-506F-45AB-B70A-FE827493CF69

P31

Q33387696-A9A41099-F4F2-4DB7-9456-2A8DCFE25AE4

P356

Q33387696-A81DDFE1-E8CF-4332-ABD2-8BAA302B024E

P433

Q33387696-D13CBDA6-FBA9-4C6F-A84B-63AC83647BDD

P478

Q33387696-1F1D5B8C-3373-4439-BEF9-BC40A2CF631D

P577

Q33387696-34A6066D-6A42-4C8F-AE52-4A3C2C4A440F

P5875

Q33387696-1CAEDE57-141D-495A-A38B-954268CFD2BB

P6179

Q33387696-59B25933-4321-4E45-A4E6-38DEA35304AE

P698

Q33387696-F32795ED-9E1A-4D6C-9F9F-1065A0B32B11

P356

S10120-009-0524-9

P1433

P1476

Weekly paclitaxel for heavily ...... il, irinotecan, and cisplatin.

@en

P2093

Akiko Todaka

http://www.w3.org/2001/XMLSchema#string

Akira Fukutomi

http://www.w3.org/2001/XMLSchema#string

Hideharu Tomita

http://www.w3.org/2001/XMLSchema#string

Hirofumi Yasui

http://www.w3.org/2001/XMLSchema#string

Keisei Taku

http://www.w3.org/2001/XMLSchema#string

Kentaro Yamazaki

http://www.w3.org/2001/XMLSchema#string

Narikazu Boku

http://www.w3.org/2001/XMLSchema#string

Nozomu Machida

http://www.w3.org/2001/XMLSchema#string

Rai Shimoyama

http://www.w3.org/2001/XMLSchema#string

Shuichi Hironaka

http://www.w3.org/2001/XMLSchema#string

P2860

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer.

Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients.

P2888

s10120-009-0524-9

P304

206-211

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10120-009-0524-9

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40835177

http://www.w3.org/2001/XMLSchema#string

P6179

1045267776

http://www.w3.org/2001/XMLSchema#string

P698

20047125

http://www.w3.org/2001/XMLSchema#string